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ABSTRACT: (454 words) 
Objectives: Red cell alloimmunisation affects up to 0.6% of all live births, and can be 
successfully treated with intrauterine fetal blood transfusion. Fetal middle cerebral 
artery (MCA) Doppler peak systolic velocity (PSV) is a non-invasive test, to identify 
fetal anaemia and requiring intrauterine transfusion (IUT). Traditionally, timing of 
subsequent IUTs has involved estimating a fall in fetal haematocrit of 1% per day, or 
a fall in fetal haemoglobin of 0.3g/dL per day. 
We conducted a pragmatic multi-centre randomised trial to evaluate whether Doppler 
MCA-PSV in the fetus that has undergone one IUT for anaemia secondary to red cell 
alloimmunisation was non-inferior to timing IUT by timing based on predicting the 
fall in fetal haematocrit or fetal haemoglobin, without compromising infant 
haemoglobin at birth. 
Methods: We conducted an international, multi-centre randomised trial. 
Women with pregnancies complicated by fetal anaemia secondary to red cell 
alloimmunisation (due to any antibody alone or in combination) as indicated by the 
need to undergo a single IUT were eligible for inclusion. 
Women were randomised to the Timing of Transfusion by MCA-PSV Group 
(ultrasound determination of the fetal MCA-PSV, with a serial upward trend with 
values >1.5MoM considered indicative of the need for another IUT), or to the Timing 
of Transfusion by Prediction of the Fall in Fetal Haematocrit (Hct) Group 
(subsequent IUT’s timed according an estimated fall in fetal Hct of 1% per day or 
fetal haemoglobin of 0.3g/dL per day, to maintain the fetal haemoglobin between 7-
10g/dL). 
The primary study outcome was infant haemoglobin measured at birth. 
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The trial was registered on the Australian and New Zealand Clinical Trials Register 
(ACTRN12608000643370). 
Results: We randomised 71 women (36 to the MCA-PSV Group; and 35 to the Fall in 
Fetal Hct. Group) from 13 centers in Australia, New Zealand, Canada, United 
Kingdom, Ireland, Belgium, and Argentina. 
The median gestational age at randomization was 30.3 weeks, and the majority of 
women were Caucasian and non-smokers; 9.9% of women had Kell 
alloimmunisation, and 14% of fetuses were hydropic at their first IUT.  
There were no statistically significant differences between the two treatment groups 
with regards to mean haemoglobin at birth (MCA-PSV Group 103.6+38.2g/dL versus 
Fall in Fetal Hct Group 120.3+31.4g/dL; adjusted mean difference -15.6; 95% CI -
32.4 to 1.3; p=0.070)), or the number of IUTs performed after randomisation (MCA-
PSV Group 1.75 (+1.79) versus Fall in Fetal Hct Group 1.80 (+1.32); adjusted 
relative risk aRR 0.88; 95% confidence interval (CI) 0.61 to 1.26; p=0.474). There 
were no statistically significant differences between the two groups in the risk of 
adverse infant outcomes related to alloimmunisation, or procedure related 
complications.  
Conclusions: Both Doppler MCA-PSV measurement and estimating the fall in fetal 
haematocrit or haemoglobin can be used to time second and subsequent IUTs.  
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INTRODUCTION: 
Middle cerebral artery (MCA) Doppler peak systolic velocity (PSV) identifies the 
fetus at risk of anaemia and requiring intrauterine transfusion (IUT).1 Originally 
described by Mari,2 a PSV above 1.5 multiples of the median (MoM) identified 
moderate or severe fetal anaemia with sensitivity 100%, and false positive rate (FPR) 
12%.2, 3 Despite limitations,4 MCA-PSV is widely used, compares favourably with 
amniotic fluid bilirubin concentrations,5 and has largely replaced serial amniocentesis 
in managing red cell alloimmunisation.  
 
Traditionally, timing of subsequent IUTs involves estimating the rate of red cell 
destruction,6-8 either by fall in fetal haematocrit,9 or haemoglobin.10 Correction of 
fetal anaemia following IUT normalises fetal MCA-PSV measurements,11 extending 
potential use to time second and subsequent procedures.10, 12-15 However, as 
highlighted by Moise, this is not supported by available data. 16  
 
Detti and colleagues13 used a MCA-PSV >1.69MoM to correctly identify all fetuses 
with severe anaemia following a single IUT, with a false positive rate of 6%. 
However, following two or more IUTs, MCA-PSV values above 1.5MoM have 
variably identified severe fetal anaemia with sensitivity between 84 and 100%,10, 14, 15 
with false positive rates of the order of 50%.10, 15 Indeed, a recent study has indicated 
that, particularly after second IUTs, formulae to estimate red cell destruction are more 
accurate than MCA-PSV.17 
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We conducted a pragmatic trial to evaluate whether timing of second and subsequent 
IUTs with Doppler MCA-PSV was non-inferior to estimating the fall in fetal 
haematocrit or haemoglobin, without compromising haemoglobin at birth. 
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METHODS: 
Study Design: A multi-centre, randomised controlled trial. 
 
Inclusion Criteria: Women with a singleton pregnancy complicated by fetal anaemia 
secondary to red cell alloimmunisation from any red cell antibody as indicated by the 
need to have performed a single IUT were eligible to participate.   
 
Exclusion Criteria: Pregnant women whose fetus had anaemia secondary to any 
other cause, or with known chromosomal anomalies were ineligible.  
 
Trial Entry: Eligible women were identified after the decision was made to proceed 
with the first IUT, and provided written informed consent to participate.  
 
Randomisation: We used an on-line randomisation service with computer generated 
schedule using balanced variable blocks, and stratification for the presence or absence 
of hydrops at first IUT, type of antibody (Kell versus other), and centre of birth. 
Women were randomized to Timing of Transfusion by MCA-PSV Group (with a 
serial upward trend and MCA-PSV values >1.5MoM indicative of the need for 
another IUT), or to the Timing of Transfusion by Estimating the Fall in Fetal Hct 
Group (subsequent IUT’s timed according an estimated fall in fetal Hct of 1% per 
day). 
 
Treatment Schedules:  
Timing of Transfusion by MCA-PSV Group - Women underwent serial ultrasound 
examinations performed in a standard fashion3 and at a frequency determined by 
	 9	
individual clinicians experienced in the management of fetal alloimmunisation. In 
short, measurements were made in the absence of fetal breathing movements, with the 
woman in a semi-recumbent position. An axial section was obtained through the fetal 
brain, caudal to the level required for the measurement of the biparietal diameter, with 
identification of the middle cerebral artery using colour or power Doppler settings, 
and angle of insonation of 0-10 degrees. Angle correction did not exceed 30 degrees. 
The sample volume was placed near the internal carotid artery, and a measurement of 
the peak Doppler waveform taken after obtaining five representative waveforms.  
Consistent with practices within each participating fetal medicine unit, the MCA-PSV 
value was recorded on standardised, and an upward serial trend in values consistently 
>1.50MoM considered indicative of the need for IUT. The new identification of 
ascites and/or hydrops was additionally considered indicative of the need for IUT, 
regardless of the MCA-PSV value.  
 
Timing of Transfusion by Estimation of the Fall in Fetal Hct Group - Women had 
the timing of IUTs planned using standard criteria to predict the rate of red cell 
destruction and development of anaemia, based on gestational age, haemoglobin prior 
to IUT, and haemoglobin at IUT completion.6-8 A fall in fetal haematocrit of 1% per 
day,9 or fetal haemoglobin of 0.3g/dL per day, was estimated, with IUT undertaken 
according to the usual practices within each center, to maintain the fetal haemoglobin 
between 7-10g/dL.10  
 
Both treatment groups:  
At a gestation beyond 24 weeks, women were administered antenatal corticosteroids 
for fetal lung maturation.1, 18 Blood transfused was fresh, matched to the woman’s 
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blood group, CMV negative, and irradiated, with haematocrit between 75-80%. IUTs 
were performed under ultrasound guidance by appropriately trained staff.1 The site of 
transfusion (umbilical cord, intrahepatic vein, or intra-peritoneal), and use of fetal 
paralysis was at the discretion of individual clinicians, in accordance with individual 
and institutional practices.1, 19, 20 The transfused blood volume was determined 
considering gestational age, estimated fetal weight, and pre-transfusion hemoglobin,1, 
21 with a post transfusion specimen obtained where possible. The target post 
transfusion haemoglobin was a deficit of 4g/dL below the mean for gestational age.6, 7 
Following the procedure, monitoring of the fetal heart rate and uterine activity were 
undertaken.  
 
Decisions relating to the timing of last IUT and of optimal timing of birth for women 
with red cell alloimmunisation are uncertain, with recommendations for birth ranging 
from after 32 weeks22 to 3623 or 38 weeks gestation.1 In the context of this pragmatic 
trial, these decisions were made following discussion between the woman and her 
caregivers. At birth, a cord blood sample was taken to estimate haemoglobin, and/or 
haematocrit. Clinical outcomes were abstracted from case notes after birth. The 
woman and her caregivers were not blinded to treatment allocation, although where 
possible, staff assessing outcomes were blind to treatment allocation.  
 
Outcomes 
The primary outcome was infant cord blood haemoglobin at birth.  
 
A range of secondary outcomes included: 
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1. Adverse infant outcomes related to alloimmunisation (one or more of stillbirth 
(intrauterine fetal death after trial entry and prior to birth); neonatal death (death 
of a live-born infant before 28 days of age); severe fetal anaemia (at the time of 
second or any subsequent transfusion, defined as pre-transfusion haemoglobin ≥ 
5 standard deviations below the mean for gestational age,	with the mean Hb for 
gestational age defined according to the following formula:  
Mean Hb = 11 +(GAweeks – 17) x 0.19);6 severe anaemia at birth (haemoglobin ≥5 
standard deviations below the mean for gestational age); or neonatal exchange 
transfusion). 2. Procedure related complications necessitating emergency birth (including one or 
more of the following within one week of the procedure: preterm pre-labour 
ruptured membranes (PPROM); preterm labour; chorioamnionitis; placental 
abruption or antepartum haemorrhage).	3. Infant complications related to alloimmunisation (including preterm birth before 
34 weeks gestation; jaundice requiring treatment; admission to the neonatal 
intensive care unit; neonatal top-up transfusion).	4. Maternal complications including antepartum haemorrhage or abruption; preterm 
premature rupture membranes; threatened preterm labour; chorioamnionitis.	
5. Number of IUTs after randomisation. 
 
Sample Size 
The sample size and primary outcome were modified prior to finalising trial data, and 
before any of the planned analyses were performed, to account for slower than 
anticipated recruitment, and to be reflective of the available funding. Assuming a 
standard deviation in infant haemoglobin of 1g/dL, a sample of 35 participants per 
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group (70 in total) provides 80% power (two-sided alpha=0.05) to detect non-
inferiority with a non-inferiority margin of 0.6 g/dL. 
The original sample size was 536 women, to detect a 30% reduction in a primary 
composite adverse outcome (stillbirth, neonatal death, severe fetal anaemia, severe 
anaemia at birth, neonatal exchange transfusion), with 5% significance level, and 90% 
power. 
 
Analysis and Reporting of Results 
Analyses used an intention-to-treat approach. Baseline characteristics of women were 
examined as an indication of comparable treatment groups, and included maternal 
age, race, height, weight, smoking history, past obstetric history (including previous 
alloimmunised pregnancy; past preterm birth or perinatal loss related to 
alloimmunisation). No imputation was performed for missing data. 
 
The effect of treatment was estimated using linear regression models for continuous 
outcomes, log binomial regression for binary outcomes, and log Poisson regression 
for count outcomes.  Estimates are difference in means (MCA-PSV – Fall in 
Haematocrit), relative risk (MCA-PSV/Fall in Haematocrit) and rate ratio (MCA-
PSV/Fall in Haematocrit) respectively, along with 95% confidence intervals.  For 
number of transfusions, an offset was included for number of days between 
randomization and delivery. 
 
Both unadjusted and adjusted analyses were performed, adjusted analyses including 
the stratification variables presence of hydrops and antibody type (Kell vs other) as 
covariates. A small number of events were observed for many outcomes, which led to 
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convergence issues with the models. Where there were too few events to allow for 
adjustment, only unadjusted analyses were performed; where there were too few 
events for any modelling, a Fishers Exact test was performed. 
 
Trial Registration 
The trial was registered on the Australian and New Zealand Clinical Trials Register  
(ACTRN12608000643370).  
 
  
	 14	
RESULTS: 
Between October 2009 and October 2013, 75 women were recruited. One woman had 
3 affected pregnancies, with data pertaining to the first randomisation only included, 
and two women were randomised in error. A total of 71 women were randomised, 36 
to the MCA-PSV Group, and 35 to the Fall in Fetal Hct Group (Figure 1). Baseline 
characteristics were similar between the two randomised groups (Table 1). The mean 
age of participating women was 33.6 years (+ 4.7years), and gestational age at 
randomisation 30.3 weeks (interquartile range (IQR) 27.7 to 32.00). Overall 60.6% of 
participants were Caucasian, and 25.4% were Hispanic. Most women were non-
smokers (85.9%), had no evidence of fetal hydrops at first IUT (85.9%), with 
alloimmunisation antibodies other than Kell (90.1%).  
 
There was one stillbirth (Fall in Fetal Hct Group) in a fetus with hydrops at 31 weeks, 
which occurred between randomization and the scheduled second IUT, and 5 neonatal 
deaths (3 in the MCA-PSV group and 2 in the Fall in Fetal Hct group). Two infants in 
the MCA-PSV Group had hydrops and died following preterm birth, within the week 
following first IUT (29, and 30 weeks respectively), due to complications of 
prematurity. The third infant was born at 33 weeks gestation and died secondary to 
liver failure following multiple exchange and top-up transfusions in the postnatal 
period, and severe respiratory distress syndrome. One infant in the Fall in Fetal Hct 
Group required 5 IUTs, but died following preterm birth, and within one week of the 
last IUT at 28 weeks gestation. The infant’s haemoglobin at birth was 97g/dL, and 
complications of prematurity were compounded by an undiagnosed complex 
congenital cardiac lesion. The second infant was born at 33 weeks gestation within a 
	 15	
week of the second IUT. Complications of prematurity were compounded by sepsis 
and multi-organ failure. 
 
There were no statistically significant differences between the two treatment groups 
with regards to mean haemoglobin (MCA-PSV Group 103.6+38.2g/dL versus Fall in 
Fetal Hct Group 120.3+31.4g/dL; adjusted mean difference (aMD) -15.6; 95% CI -
32.4 to 1.3; p=0.070), or mean number of IUTs after randomisation (MCA-PSV 
Group 1.75 (+1.79) versus Fall in Fetal Hct Group 1.80 (+1.32); adjusted relative risk 
aRR 0.88; 95% confidence interval (CI) 0.61 to 1.26; p=0.474) (Table 2). There were 
no statistically significant differences in gestational age at birth (MCA-PSV Group 
35.23+2.30weeks versus Fall in Fetal Hct Group 35.07+2.28weeks; aMD 0.26; 95% 
CI -0.75 to 1.27; p=0.613); preterm birth before 34 weeks (MCA-PSV Group 9/36 
(25.00%) versus Fall in Fetal Hct Group 7/35 (20.00%); aRR 1.36; 95% CI 0.61 to 
3.05; p=0.458); or birth weight (MCA-PSV Group 2581.11+604.03g versus Fall in 
Fetal Hct Group 2602.69+591.34g; aMD -49.79; 95% CI -246.14 to 146.57; 
p=0.619). While a high proportion of infants were admitted to the neonatal unit, 
(MCA-PSV Group 28/35 (80.00%) versus Fall in Fetal Hct Group 22/34 (67.65%); 
aRR 1.20; 95% CI 0.89 to 1.60; p=0.231), there were no statistically significant 
differences in exchange transfusion (MCA-PSV Group 14/35 (40.00%) versus Fall in 
Fetal Hct Group 9/34 (26.47%); aRR 1.42; 95% CI 0.71 to 2.83; p=0.316); top-up 
transfusion (MCA-PSV Group 21/35 (60.00%) versus Fall in Fetal Hct Group 19/34 
(55.88%); aRR 1.05; 95% CI 0.70 to 1.57; p=0.827); or jaundice requiring treatment 
MCA-PSV Group 29/34 (85.29%) versus Fall in Fetal Hct Group 30/34 (88.24%); 
aRR 1.06; 95% CI 0.91 to 1.22; p=0.460) (Table 2). 
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There were no statistically significant differences in procedure related or maternal 
complications (Table 3).  
 
There was no evidence to suggest that outcomes varied according to the presence of 
hydrops at first IUT, or the responsible antibody (data not shown). 
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DISCUSSION: 
Principal Findings 
Doppler MCA-PSV measurement is not inferior to estimating the fall in fetal 
haematocrit to time second and subsequent IUTs, although infants born following 
Doppler MCA-PSV to time IUTs had a non-statistically significant trend towards 
lower mean haemoglobin at birth (103.6g/dL vs 120.3g/dL), and more frequent need 
for neonatal exchange transfusion (40.0% vs 26.5%). There were no significant 
differences identified with regards to other alloimmunisation or procedure related 
complications.  
 
Comparisons with other studies 
The procedure related complication risk in our trial was 2.8%, with an overall survival 
rate of 93%, both of which are consistent with the 3.1%, and greater than 90%, 
respectively reported in the literature.20 In contrast, Zwiers and colleagues have 
recently reported their extensive 27-year experience involving almost 1,700 
transfusion procedures, from a single tertiary referral center.24 In this cohort, survival 
improved from approximately 89% to 97%, and procedure related complications 
declined from 3.4% to 1.2% for the time periods 1998-2001 and 2001-2014 
respectively. These high survival rates and low complication rates24 are likely the 
“best case scenario”, reflective of both clinician experience and volume of procedures 
undertaken, as compared with the necessity of our more pragmatic study design.  
 
Approximately 25% of infants in our trial had severe anaemia at birth, with 85% 
receiving phototherapy for treatment of jaundice. One third of infants received at least 
one exchange transfusion, and 60% at least one top-up transfusion. Infants in the 
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MCA-PSV group tended to a lower haemoglobin at birth and were more likely to 
receive exchange transfusion, when compared with estimating the fall in fetal 
haematocrit / haemoglobin. While these differences were not statistically significant, 
likely reflecting the sample size, they are clinically significant in neonatal care.  
 
Neonatal outcomes reported from our trial are not directly comparable with other 
study populations reported in the literature. All infants in our trial population required 
at least one IUT, in contrast to other reports, where outcome comparisons have largely 
reflected the presence or absence of an antenatal transfusion procedure. Van Kamp 
reported neonatal outcomes for 191 infants born after any IUT.25 While the mean 
haemoglobin reported at birth was consistent with our findings, it is difficult to 
compare other outcomes, with the median number of exchange and top-up 
transfusions reported, rather than an indication of the number of infants requiring this 
treatment.25  
 
A study from the United Kingdom followed 28 women with MCA-PSV.26 Reported 
neonatal complication rates were lower than identified in our trial with 36% of infants 
requiring phototherapy for jaundice, 25% an exchange transfusion, and 14% a top-up 
transfusion.26 DeBoer and colleagues have reported outcomes for 89 infants with 
Rhesus haemolytic disease, where 52 infants required an IUT.27 In this series, while 
71% of infants who required an IUT also received an exchange transfusion, they 
required less phototherapy, but more top-up transfusions, when compared with infants 
who were not treated in the antenatal period,27 although again, the comparator was 
infants who did not require an IUT. 
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Strengths & Weaknesses 
To our knowledge, this is the first randomized trial evaluating Doppler MCA-PSV to 
time second and subsequent IUTs for red cell alloimmunisation. We utilized robust 
methodology, pre-specified relevant maternal and infant outcomes, and followed a 
pre-specified analysis plan.  
 
While the primary outcome and sample size was modified from the original trial 
registration, this occurred prior to finalising data collection, before undertaking any 
pre-specified analyses, and was made after accounting for slower than anticipated 
recruitment and the final allocated funding. The trial is adequately powered to identify 
relatively small differences in haemoglobin concentration at birth between the two 
treatment practices, but not differences in less common clinical outcomes. 
 
We encountered several barriers in conducting this trial, reflecting the need to involve 
multiple centres internationally to study a relatively uncommon condition. We 
experienced considerable delays in commencing recruitment, with the mean time to 
obtain ethical approval in centres where recruitment occurred being 305 days (range 
92 to 608 days). This delay was greater in centres where the ethical approval process 
was commenced, but where recruitment did not occur (mean 518 days; range 153 to 
1,095 days). Many clinical collaborators indicated that time pressures and a lack of 
research support hampered their participation, although provision of dedicated 
research support at each site was not possible with only modest financial 
reimbursement provided per participant recruited. Unfortunately, there were 
considerable time delays between investigators providing agreement to participate and 
securing funding. Over this time there was a shift in clinical equipoise, such that 
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many large referral centres internationally routinely used MCA-PSV to time second 
and subsequent IUTs, and were therefore no longer willing to participate.  
 
Conclusions 
Our findings indicate that both Doppler MCA-PSV measurement and estimating the 
fall in fetal haematocrit or haemoglobin can be used to time second and subsequent 
IUTs. However, the trend towards lower infant haemoglobin, increased need for 
exchange transfusion, and the increased frequency of visits for ultrasound surveillance 
associated with MCA-PSV Doppler assessment, have resource implications for the 
woman, and healthcare facility, and are valid considerations in determining the most 
appropriate method to time IUTs.  
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